Elahere
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Life-prolonging drug for advanced ovarian cancer gets go-ahead in England
Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 yearsHundreds of women with hard-to-treat ovarian cancer can now be offered a new life-prolonging treatment, after NHS England approved its introduction. It is the first new drug for resistant ovarian cancer to be approved for more than 20 years. Ovarian is the 18th most common type of cancer globally, affecting more than 300,000 women a year.
Ovarian cancer: What is the new drug approved for the NHS in England?
A new drug to treat resistant ovarian cancer, and the first to be approved in over two decades, has been approved for patients in the NHS in England. What is the new drug?Mirvetuximab soravtansine (marketed as Elahere), developed by AbbVie, is an advanced, targeted treatment that combines a “homing” antibody with a cancer destroying drug. Often described by scientists as a “biological missile” or “trojan horse” therapy, the drug is already available in the US and Europe.
Life-prolonging drug for advanced ovarian cancer gets go-ahead in England
Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 yearsHundreds of women with hard-to-treat ovarian cancer can now be offered a new life-prolonging treatment, after NHS England approved its introduction. It is the first new drug for resistant ovarian cancer to be approved for more than 20 years. Ovarian is the 18th most common type of cancer globally, affecting more than 300,000 women a year.
Life-prolonging drug for advanced ovarian cancer gets go-ahead in England
Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 yearsHundreds of women with hard-to-treat ovarian cancer can now be offered a new life-prolonging treatment, after NHS England approved its introduction. It is the first new drug for resistant ovarian cancer to be approved for more than 20 years. Ovarian is the 18th most common type of cancer globally, affecting more than 300,000 women a year.